FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Clinical trials for FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Drug pill combo tested for Tough-to-Treat ovarian cancer
Disease control OngoingThis study is testing a combination of two oral medications, olaparib and cediranib, for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned after previous treatment. The goal is to see if taking these two drugs together can help control the cancer's gr…
Matched conditions: FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 08:22 UTC
-
New drug duo battles Tough-to-Treat ovarian cancer
Disease control OngoingThis study is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to standard platinum-based chemotherapy. It aims to see if taking two oral drugs, cediranib and olaparib, together works better than taking either drug alone or…
Matched conditions: FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 08:20 UTC
-
Doctors test 'Trojan Horse' stem cells carrying Cancer-Killing virus
Disease control OngoingThis early-phase trial is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Researchers are using a patient's own fat-derived stem cells to carry a specially engineered measles virus directly to the cancer…
Matched conditions: FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 04, 2026 08:20 UTC
-
Trial tests weekly vs. standard chemo for Tough-to-Treat cancers
Disease control OngoingThis large study aimed to find out if giving a key chemotherapy drug (paclitaxel) once a week is better than giving it once every three weeks for treating advanced ovarian, fallopian tube, or primary peritoneal cancer. All participants also received another chemotherapy drug (car…
Matched conditions: FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for Hard-to-Treat ovarian cancer? early trial tests drug combo
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding …
Matched conditions: FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat ovarian cancers in early trial
Disease control OngoingThis early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…
Matched conditions: FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New targeted attack on tough ovarian cancer tested against standard care
Disease control OngoingThis study is for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It compares a new two-drug combination (bevacizumab + anetumab ravtansine) against a standard two-drug combination (bevacizumab + paclit…
Matched conditions: FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC